Professor Trent Woodruff leads a research team at The University of Queensland, Australia, and has over 20 years research training in complement pharmacology and neuroimmunology. He is an NHMRC Leadership fellow and President-elect of the International Complement Society. Professor Woodruff’s research revolves around the innate immune system, and its role in neurodegenerative diseases such as Parkinson's disease and motor neuron disease. Using a series of potent and orally active complement and inflammasome inhibitors developed in collaboration with his group, he is elucidating the therapeutic potential of targeting neuroinflammation to treat brain disease. He has an established track record of translating basic laboratory discoveries into human clinical trials, with two of his in-house drug discoveries currently undergoing clinical testing in neurological diseases through successful commercialisation and licensing deals.